Influenza A virus continuously infects humans and the antigenic shifts of this respiratory virus
enable it to cross the species barrier, threatening public health with the risk of pandemics …

Influenza viruses cause severe diseases and mortality in humans on an annual basis. The
current influenza virus vaccines can confer protection when they are well-matched with the …

There is increasing evidence to suggest that antibodies directed toward influenza A virus
(IAV) neuraminidase (NA) are an important correlate of protection against influenza in …

Although most seasonal inactivated influenza vaccines (IIV) contain neuraminidase (NA),
the extent and mechanisms of action of protective human NA-specific humoral responses …

Introduction: Currently, several universal/broadly protective influenza virus vaccine
candidates are under development. Many of these vaccines are based on strategies to …

SARS-CoV-2 and Influenza viruses are both highly transmissible airborne viruses and
causing high morbidity and mortality. Co-infection of these two viruses results in severe …

Immunization is the cornerstone of seasonal influenza control and represents an important
component of pandemic preparedness strategies. Using a bioluminescent reporter virus, we …

Influenza viruses affect millions of people worldwide on an annual basis. Although vaccines
are available, influenza still causes significant human mortality and morbidity. Vaccines …

The initial months of life reflect an extremely challenging time for newborns as a naïve
immune system is bombarded with a large array of pathogens, commensals, and other …

The conserved hemagglutinin stalk domain is an attractive target for broadly effective
antibody-based therapeutics and next-generation universal influenza vaccines. Protection …